BRIAN FELLOWS: Open Payments
NPI 1548211659 · SALEM, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,472 in 167 payments from 32 companies in 2025. Trend: 2023 $3,083 · 2024 $3,799 · 2025 $3,472
Food & beverage: $3,472
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $480 |
| AstraZeneca Pharmaceuticals LP | 16 | $418 |
| PFIZER INC. | 12 | $256 |
| Lilly USA, LLC | 10 | $230 |
| Otsuka America Pharmaceutical, Inc. | 10 | $203 |
| Teva Pharmaceuticals USA, Inc. | 11 | $194 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $171 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $129 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $128 |
Products named: REXULTI, VRAYLAR, JARDIANCE, AIRSUPRA, UBRELVY, CAPLYTA, Kerendia, AUSTEDO XR.
Industry payments across MA — which companies pay providers there.
